Corticosteroid Viscosity Control for Epidural Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions for epidural, intra-articular, or intra-lesional injections often require repeated administration due to short-term effects, and may diffuse outside the target area, necessitating higher doses and potentially causing adverse effects like arachnoiditis.
Innovation Solution
Aqueous pharmaceutical composition comprising a soluble corticosteroid, such as dexamethasone sodium phosphate, combined with a viscosity enhancing agent like sodium hyaluronate, which increases the viscosity of the composition to between 1 cP and 200 cP, allowing for sustained release and prolonged exposure at the injection site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a low viscosity pharmaceutical composition is used for epidural injection, then the composition can be easily injected and diffuses quickly, but the medication diffuses outside the target area and requires higher doses
Solution Approach 1:
The patent applies parameter changes by adjusting the viscosity of the pharmaceutical composition to a specific range (50-200 cP at 37°C) to optimize both injectability and localization. This viscosity modification prevents excessive diffusion outside the target epidural space while maintaining ease of injection through standard needles.
Solution Approach 2:
The patent uses composite materials by combining corticosteroid medication with viscosity-modifying agents (such as hyaluronic acid or carboxymethylcellulose) to create a formulation that maintains both injectability and localized retention. The composite composition achieves controlled diffusion characteristics without requiring higher drug doses.
2Reliability
If a high dose of corticosteroid is administered to ensure target area exposure, then the treatment efficacy increases, but adverse effects like arachnoiditis increase
Solution Approach 1:
The patent modifies the viscosity parameter of the pharmaceutical composition to retain medication within the target epidural space, ensuring adequate drug exposure at therapeutic doses without exceeding safe limits. This prevents arachnoiditis and other adverse effects associated with high-dose administration.
Solution Approach 2:
The viscosity-modifying agents act as intermediaries that facilitate controlled drug delivery and retention in the epidural space. These agents mediate between the need for sufficient drug concentration and the need to prevent harmful diffusion, allowing effective treatment at lower, safer doses.
3Speed
If the medication is delivered quickly to the spinal nerve, then the onset of action is rapid, but the duration of effect is short requiring repeated injections
Solution Approach 1:
The patent adjusts the viscosity parameter of the composition to achieve optimal balance between rapid delivery and prolonged retention. The modified viscosity allows quick injection and rapid onset of action while preventing premature clearance, extending the duration of therapeutic effect and reducing injection frequency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides a quick onset of action with a long-lasting effect, reducing the frequency of injections and minimizing diffusion outside the target area, thereby enhancing treatment efficacy and safety.
Implementation Method 1
a viscosity enhancing agent like sodium hyaluronate, which increases the viscosity of the composition to between 1 cP and 200 cP
Data Source
AI summary
Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises a soluble corticosteroid and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, or an intra-lesional injection.